HRSA-23-055: Ryan White HIV/AIDS Program Part B States/Territories Supplemental Grant Program
Closed
This grant is closed. A newer notice from the same program is forecast: Ryan White HIV/AIDS Program Part B States/Territories Supplemental Grant Program (HRSA-27-070). Status: Expected deadline March 15, 2027. It is in our archive of Health Resources and Services Administration notices from 2023.
Health Resources and Services Administration offered grants of up to $9.0 million to state and local governments. It expected to make about 30 awards worth $48.0 million in total. Applications closed on April 20, 2023.
From the official notice on Grants.gov, last changed January 18, 2023. Checked November 7, 2026.
- Award ceiling$9.0 million
- Total funding$48.0 million
- Expected awards30
- Cost sharingNot required
- Funding typeGrant
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| HRSA-27-070 | July 13, 2026 | Expected deadline March 15, 2027 | Forecast |
| HRSA-26-074 | June 8, 2026 | Closed July 10, 2026 | Closed |
| HRSA-25-048 | January 14, 2025 | Closed March 18, 2025 | Closed |
| HRSA-24-065 | February 27, 2024 | Closed April 30, 2024 | Closed |
| HRSA-22-034 | February 28, 2022 | Closed May 9, 2022 | Closed |
| HRSA-21-067 | February 23, 2021 | Closed May 10, 2021 | Closed |
Key dates
| Posted | January 18, 2023 |
|---|---|
| Deadline | April 20, 2023 |
Who can apply
This opportunity was open to state and local governments.
- State governments
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Under Sections 2620 and 2689(11) of the PHS Act, all States defined as all 50 States, the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, Guam, American Samoa, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, the Federated States of Micronesia, and the Republic of the Marshall Islands are eligible for RWHAP Part B supplemental funding, unless any such state/territory had an unobligated balance of more than five percent of a prior years formula funds. Tribes and tribal organizations are not eligible. However, the Coronavirus Disease 2019 (COVID-19) public health emergency has posed significant challenges for RWHAP recipients, providers, and clients to provide and access care. On February 23, 2021, HRSA HAB released a letter that waived certain statutory penalties and administrative requirements for funds awarded in FY 2020 and 2021 in accordance with the Consolidated Appropriations Act, 2021, Pub. L. 116- 260, Division M, 307. Requirements regarding the timeframe for obligation and expenditure of formula and supplemental RWHAP funds within the designated timeframe, including the requirement to submit an estimated unobligated balance and carryover request prior to the end of the grant year, and associated penalties were waived. Therefore, no states/territories will be deemed ineligible for the FY 2023 RWHAP States/Territories Part B Supplemental Grant Program.
Is this a realistic fit?
- Past HIV Care Formula Grants awards averaged $47.6 million; this notice allows up to $9.0 million per award.
- No cost sharing or match is required.
What the grant funds
This notice announces the opportunity to apply for funding under the Ryan White HIV/AIDS Program (RWHAP) States/Territories Part B Supplemental Grant Program, which includes the District of Columbia, the Commonwealth of Puerto Rico, the Virgin Islands, Guam, American Samoa, the Commonwealth of the Northern Mariana Islands, the Republic of Palau, the Federated States of Micronesia, and the Republic of the Marshall Islands. The purpose of this program is to supplement formula-based funding provided through the HIV Care Grant Program – RWHAP Part B States/Territories Formula and AIDS Drug Assistance Program (ADAP) Formula and ADAP Supplemental Awards Notice of Funding Opportunity (HRSA-22-033). States/territories use RWHAP Part B Supplemental Grant Program funding in conjunction with RWHAP Part B HIV Care Grant Program funding to develop and/or enhance access to a comprehensive continuum of high-quality care and treatment services for low-income people with HIV. To obtain funding, states/territories must demonstrate that RWHAP Part B supplemental funding is necessary to provide comprehensive HIV care and treatment services for people with HIV in the state/territory. Proposed activities should include the provision of core medical and/or support services, as defined in HRSA HAB Policy Clarification Notice (PCN) 16-02: RWHAP Services: Eligible Individuals and Allowable Uses of Funds, and other activities to ensure responsiveness to unmet needs. States/territories must describe how proposed activities will address unmet needs and improve client-level health outcomes across the HIV care continuum, including viral suppression. Eligible RWHAP Part B states/territories that are focus areas, or have counties that are focus areas, for the Ending the HIV Epidemic in the U.S. (EHE) initiative should consider if there is an increased need for RWHAP Part B supplemental funding due to the EHE initiative efforts using criteria below. As required in section 2620(b) of the Public Health Service (PHS) Act, states/territories must demonstrate the severity of the need for RWHAP Part B supplemental funding using quantifiable data in one or more of the following areas: 1. The unmet need for such services, as determined under section 2617(b) of the PHS Act. 2. An increasing need for HIV/AIDS-related services, including relative rates of increase in the number of cases of HIV/AIDS. 3.
Who has won HIV Care Formula Grants grants before
From fiscal 2021 to 2025, HIV Care Formula Grants (93.917) awarded $6.3 billion across 133 grant awards, an average of $47.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| California Department of Public Health | California | 3 | $742 million |
| Health Research, Inc. | New York | 2 | $663 million |
| Florida Department of Health | Florida | 3 | $643 million |
| Department of State Health Services | Texas | 3 | $636 million |
| State of Georgia Department of Public Health | Georgia | 3 | $369 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, HRSA-27-070, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-23-055 still open?
No. It closed on April 20, 2023. A newer notice is forecast: HRSA-27-070, expected deadline March 15, 2027.
Who can apply for Ryan White HIV/AIDS Program Part B States/Territories Supplemental Grant Program?
Health Resources and Services Administration accepted applications from state and local governments. The notice adds further conditions, so read its eligibility section.
What is the deadline for Ryan White HIV/AIDS Program Part B States/Territories Supplemental Grant Program?
Closed April 20, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $9.0 million each. About $48.0 million in total across about 30 awards.
Who has won HIV Care Formula Grants grants before?
The largest recipients over five fiscal years were California Department of Public Health, Health Research, Inc., Florida Department of Health. The program made 133 awards worth $6.3 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)